Dominik Maurer joined Immatics Biotechnologies GmbH in 2008.
For over 15 years, Dominik has been a leader in the field of cancer immunotherapy, specializing in human T-cell biology. He invented and developed Immatics' T-Cell Receptor (TCR) technology platform, XCEPTOR®, alongside his team. This platform enables the rapid and efficient discovery, engineering, and qualification of numerous high-affinity, high-specificity TCRs for use in Adoptive Cell Therapies (i.e., ACTengine® and ACTallo®) or TCER® bispecifics.
Dominik co-leads the Immatics Discovery Unit, where he shapes research and innovation. He is the inventor of over 25 patents and patent applications and has co-authored more than 10 publications in peer-reviewed journals, including Nature, Nature Medicine, Science Immunology, Immunity, and Lancet Oncology.
Dominik Maurer gained his Ph.D. in Immunology from the University of Tübingen, Germany.